C-reactive protein-to-lymphocyte ratio is a novel biomarker for predicting the long-term efficacy of ustekinumab treatment in ulcerative colitis

• DOI: 10.1371/journal.pone.0305324
• Publication Date: 2024-08-29T18:52:43Z
• Authors: Ryoji Koshiba; Kazuki Kakimoto; Noboru Mizuta; Keijiro Numa; Naohiko Kinoshita; Kei Nakazawa; Yuki Hirata; Takako Miyazaki; Kazuhide Higuchi; Shiro Nakamura; Hiroki Nishikawa
• Keywords: Male; Adult; Science; Q; Remission Induction; R; Middle Aged; Prognosis; C-Reactive Protein; Treatment Outcome; Medicine; Humans; Ustekinumab; Colitis, Ulcerative; Female; Lymphocytes; Lymphocyte Count; Biomarkers; Research Article; Retrospective Studies

Background and aim Ustekinumab, a new anti-interleukin-12/23 antibody, is an effective treatment for ulcerative colitis; however, data regarding predictive factors of its efficacy are limited. Predicting treatment efficacy in advance would be useful for selecting a therapeutic agent. This study aimed to identify biomarkers that can predict the long-term outcome of ustekinumab treatment.

Materials and methods We retrospectively reviewed the records of patients with active ulcerative colitis treated with ustekinumab at Osaka Medical and Pharmaceutical University Hospital from June 2020 to January 2023. We divided patients into non-remission and remission groups, and examined whether baseline biomarkers, including C-reactive protein-to-lymphocyte ratio, and early treatment response could predict clinical remission at week 48 of ustekinumab treatment.

Results Of the 33 patients included in the study, 21 (63.6%) were in clinical remission at week 48 of ustekinumab treatment. Baseline C-reactive protein-to-lymphocyte ratio values were significantly higher in the non-remission than in the remission group. The baseline C-reactive protein-to-lymphocyte ratio value was identified as an independent prognostic factor for clinical remission at week 48 (odds ratio: 10, 95% confidence interval: 1.6–62.4, p = 0.014), with the cutoff value of 3.353 showing excellent prognostic performance (sensitivity: 71.4%, specificity: 83.3%). Furthermore, the clinical response at week 4 (odds ratio: 10, confidence interval: 1.78–56.1, p = 0.009) and that at week 8 (odds ratio: 12, confidence interval: 2.16–66.5, p = 0.005) were significantly associated with clinical remission at week 48.

Conclusions The baseline C-reactive protein-to-lymphocyte ratio value and early treatment response are useful biomarkers to predict the long-term efficacy of ustekinumab treatment.